As of June 19, 2025, Angion Biomedica Corp (ANGN) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Angion Biomedica Corp's Forward P/E to Peers
To better understand Angion Biomedica Corp's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Angion Biomedica Corp (ANGN) | - |
| Ether Capital Corp (ETHC.NE) | 91.40 |
| Catalent Inc (CTLT) | 55.81 |
| Eli Lilly and Co (LLY) | 35.98 |
| Zoetis Inc (ZTS) | 25.20 |
| Elanco Animal Health Inc (ELAN) | 15.75 |
Compared to its competitors, Angion Biomedica Corp's Forward P/E is difficult to compare due to insufficient data.